Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression‐free survival, especially in BRCA‐positive patients—A case‐control study

Abstract

HIPEC after surgical cytoreduction in patients with rEOC appears beneficial compared to systemic chemotherapy treatment alone. The benefit is even greater in BRCA mutation carriers.

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

“…There are 5 case control studies that have compared CRS and HIPEC with CRS alone [67][68][69][70][71] and all but one have shown a statistically significant benefit of CRS and HIPEC over CRS alone. These studies are listed in Table 3.…”

Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis

“…comparative studies (8 HIPEC + CRS+chemotherapy vs CRS+chemotherapy [15, 24-30] & HIPEC+CRS vs systemic chemotherapy alone[31]) and 28 HIPEC+CRS cohort…”

Hyperthermic Intraperitoneal Perfusion Chemotherapy and Cytoreductive Surgery for Controlling Malignant Ascites From Ovarian Cancer

“…Of course, CRS-HIPEC improves survival for patients with OC and malignant ascites only when a complete CRS is achieved, as those with incomplete CRS have a poor prognosis. 1,25,37,41 In the present study, the median OS of patients with malignant ascites from OC who had complete CRS was 52 months, whereas incomplete resection led to an OS of only 15.6 months.…”

“…1 Long-term OS has been reported to be less than 8 months in the most end-stage patients with OC. 25,37,41 The efficacy of HIPEC and CRS for treating PC originating from advanced OC is well established, and the survival obtained using HIPEC + CSR seems to be dramatically longer than that obtained with previously reported treatment approaches. 25,37,41 The present study indicates that HIPEC + CSR can be tailored according to the patient's general condition.…”

“…25,37,41 The efficacy of HIPEC and CRS for treating PC originating from advanced OC is well established, and the survival obtained using HIPEC + CSR seems to be dramatically longer than that obtained with previously reported treatment approaches. 25,37,41 The present study indicates that HIPEC + CSR can be tailored according to the patient's general condition. Furthermore, patients in poor general health condition who are initially ineligible for CRS can receive the benefits of dCRS several days after the administration of HIPEC, which improves their health condition, thereby potentially increasing long-term survival.…”